329 related articles for article (PubMed ID: 7542533)
1. Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.
Culman J; Wiegand B; Spitznagel H; Klee S; Unger T
Br J Pharmacol; 1995 Mar; 114(6):1310-6. PubMed ID: 7542533
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
Picard P; Regoli D; Couture R
Br J Pharmacol; 1994 May; 112(1):240-9. PubMed ID: 7518304
[TBL] [Abstract][Full Text] [Related]
3. Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat.
Tschöpe C; Picard P; Culman J; Prat A; Itoi K; Regoli D; Unger T; Couture R
Br J Pharmacol; 1992 Nov; 107(3):750-5. PubMed ID: 1335337
[TBL] [Abstract][Full Text] [Related]
4. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress.
Culman J; Klee S; Ohlendorf C; Unger T
J Pharmacol Exp Ther; 1997 Jan; 280(1):238-46. PubMed ID: 8996202
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
Cellier E; Barbot L; Regoli D; Couture R
Br J Pharmacol; 1997 Oct; 122(4):643-54. PubMed ID: 9375960
[TBL] [Abstract][Full Text] [Related]
6. Substance P and neurokinin A induced desensitization to cardiovascular and behavioral effects: evidence for the involvement of different tachykinin receptors.
Culman J; Tschöpe C; Jost N; Itoi K; Unger T
Brain Res; 1993 Oct; 625(1):75-83. PubMed ID: 7694777
[TBL] [Abstract][Full Text] [Related]
7. C-FOS expression in the rat brain in response to substance P and neurokinin B.
Spitznagel H; Baulmann J; Blume A; Unger T; Culman J
Brain Res; 2001 Oct; 916(1-2):11-21. PubMed ID: 11597586
[TBL] [Abstract][Full Text] [Related]
8. Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.
Mazzone SB; Geraghty DP
Br J Pharmacol; 2000 Mar; 129(6):1121-31. PubMed ID: 10725260
[TBL] [Abstract][Full Text] [Related]
9. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
Tauer U; Zhao Y; Hunt SP; Culman J
Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
[TBL] [Abstract][Full Text] [Related]
10. Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.
Picard P; Chrétien L; Couture R
Br J Pharmacol; 1995 Apr; 114(8):1563-70. PubMed ID: 7541280
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of a 'septide-sensitive' inflammatory response in rat skin.
Ahluwalia A; Giuliani S; Maggi CA
Br J Pharmacol; 1995 Oct; 116(4):2170-4. PubMed ID: 8564245
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of intracerebroventricularly injected tachykinins in the conscious saline-loaded rat: receptor characterization.
Yuan YD; Couture R
Br J Pharmacol; 1997 Mar; 120(5):785-96. PubMed ID: 9138683
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization.
Prat A; Picard P; Couture R
Br J Pharmacol; 1994 May; 112(1):250-6. PubMed ID: 7518305
[TBL] [Abstract][Full Text] [Related]
14. Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists.
Picard P; Couture R
Br J Pharmacol; 1996 Jan; 117(2):241-9. PubMed ID: 8789375
[TBL] [Abstract][Full Text] [Related]
15. Tachykinin receptor inhibition and c-Fos expression in the rat brain following formalin-induced pain.
Baulmann J; Spitznagel H; Herdegen T; Unger T; Culman J
Neuroscience; 2000; 95(3):813-20. PubMed ID: 10670449
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the tachykinin receptors involved in spinal and supraspinal cardiovascular regulation.
Couture R; Picard P; Poulat P; Prat A
Can J Physiol Pharmacol; 1995 Jul; 73(7):892-902. PubMed ID: 8846427
[TBL] [Abstract][Full Text] [Related]
17. Study of SR 142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pig.
Roccon A; Marchionni D; Nisato D
Br J Pharmacol; 1996 Jul; 118(5):1095-102. PubMed ID: 8818331
[TBL] [Abstract][Full Text] [Related]
18. Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioral responses in conscious rats.
Itoi K; Tschöpe C; Jost N; Culman J; Lebrun C; Stauss B; Unger T
Eur J Pharmacol; 1992 Sep; 219(3):435-44. PubMed ID: 1385176
[TBL] [Abstract][Full Text] [Related]
19. Involvement of tachykinin receptors in oedema formation and plasma extravasation induced by substance P, neurokinin A, and neurokinin B in mouse ear.
Inoue H; Nagata N; Koshihara Y
Inflamm Res; 1996 Jul; 45(7):316-23. PubMed ID: 8841832
[TBL] [Abstract][Full Text] [Related]
20. The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.
Deschamps K; Couture R
Br J Pharmacol; 2005 Jul; 145(6):712-27. PubMed ID: 15895109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
